The main problem with the product being sold in retail is
The main problem with the product being sold in retail is that most people have insurance and insurance can cover up to 3 tests a day. So if your copay is only $5.00, $10.00 or $20.00 for 90 test strips most people will continue to use insurance and the name brand.
That is John Cesario, TAUG's paid consultant, crap. The entire market changed in 2014 and then changed again last October. I know that you TAUG thugs think you know everything, but you don't.
Next time bring a link to your bash.
2
Decision Diagnostics Corp (DECN) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Unveiling the New Betblast Features for Gamers In a digital age where online gambling is immensely popular, players are consistently on the lookout for platforms that provide more than just entertainment but also real, significant rewards. One name that has emerged as a favorite among players for offering exceptional wins and rapid payouts is Betblast. As discussions...
Continue Reading
Kinetic Business Introduces an Innovative Internet Solution Kinetic Business is stepping into the spotlight with an exciting new product that caters specifically to the needs of small businesses. Their latest offering, known as Business Ready Internet, aims to revolutionize how small enterprises manage their connectivity, security, and overall operational efficiency....
Continue Reading
Ship-to-Shore Cranes Market Overview As we look towards the future of the Ship-to-Shore (STS) cranes market, predictions indicate a significant expansion, with market size anticipated to reach USD 4.06 billion by 2032. This growth represents a compound annual growth rate (CAGR) of 4.41% from 2025 to 2032. The increasing emphasis on technological advancements in port...
Continue Reading
Chicago Rivet & Machine Co. Announces Dividend Decision Chicago Rivet & Machine Co. (NYSE American: CVR) has made an important announcement regarding its dividend for shareholders. The Board of Directors has declared a quarterly cash dividend of $0.03 per share. This will be paid out to all shareholders who are recorded as of December 5 of the current fiscal year. While...
Continue Reading
Understanding the AstraZeneca PLC Class Action A class action lawsuit has been initiated on behalf of stockholders who purchased shares of AstraZeneca PLC (NASDAQ: AZN) between specific dates. Robbins LLP is actively reminding these investors of the critical lead plaintiff deadline. This class action highlights important allegations surrounding AstraZeneca and offers...
Continue Reading
